Semicarbazide protection from in vivo oxidant injury of vascular tissue by allylamine

S. Awasthi, P. J. Boor

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Allylamine is a specific cardiovascular toxin that causes vascular and myocardial lesions. Previous studies showed that allylamine-induced chronic lesions are markedly reduced by semicarbazide, an inhibitor of semicarbazide-sensitive amine oxidase (SSAO), and that allylamine is metabolized to the aldehyde, acrolein, by SSAO. We hypothesized that inhibitors of SSAO might reduce the acute cardiovascular toxicity of allylamine. To test our hypothesis, we fed 150 mg kg allylamine to semicarbazide-pretreated (3 h; 98 mg kg) rats. Animals were sacrificed 1 h after allylamine treatment. Aorta, epicardium, and endocardium were assayed for SSAO, glutathione peroxidase, catalase, thiol status and lipid peroxidation. SSAO activity was decreased significantly in aorta, epicardium and endocardium. Activity was 30-times higher in aorta than in epicardium and endocardium. A striking decrease in malonalydehyde level (lipid peroxidation) was found in aorta of pretreated rats as compared to allylamine-only treated rats. The reduction of free-SH content in aortic mitochondria was also attenuated in pretreated rats. Changes were not so marked in epicardium and endocardium. These results suggest that in vivo pretreatment with semicarbazide at least partially protects aortic mitochondria from allylamine toxicity. The mechanism can be explained on the basis of the fact that semicarbazide inhibits acrolein formation in allylamine-treated rats.

Original languageEnglish (US)
Pages (from-to)157-163
Number of pages7
JournalToxicology Letters
Volume66
Issue number2
DOIs
StatePublished - 1993

Fingerprint

Allylamine
Vascular System Injuries
Oxidants
Amine Oxidase (Copper-Containing)
Tissue
Endocardium
Pericardium
Rats
Aorta
Acrolein
Mitochondria
Lipid Peroxidation
Toxicity
Lipids
carbamylhydrazine
Glutathione Peroxidase
Sulfhydryl Compounds
Aldehydes
Catalase
Blood Vessels

Keywords

  • Allylamine
  • Aorta
  • Cardiovascular toxicity
  • Lipid peroxidation
  • Semicarbazide
  • Semicarbazide-sensitive amine oxidase (SSAO)

ASJC Scopus subject areas

  • Toxicology

Cite this

Semicarbazide protection from in vivo oxidant injury of vascular tissue by allylamine. / Awasthi, S.; Boor, P. J.

In: Toxicology Letters, Vol. 66, No. 2, 1993, p. 157-163.

Research output: Contribution to journalArticle

Awasthi, S. ; Boor, P. J. / Semicarbazide protection from in vivo oxidant injury of vascular tissue by allylamine. In: Toxicology Letters. 1993 ; Vol. 66, No. 2. pp. 157-163.
@article{2bdd790616cc49ad8f17582aadc6feac,
title = "Semicarbazide protection from in vivo oxidant injury of vascular tissue by allylamine",
abstract = "Allylamine is a specific cardiovascular toxin that causes vascular and myocardial lesions. Previous studies showed that allylamine-induced chronic lesions are markedly reduced by semicarbazide, an inhibitor of semicarbazide-sensitive amine oxidase (SSAO), and that allylamine is metabolized to the aldehyde, acrolein, by SSAO. We hypothesized that inhibitors of SSAO might reduce the acute cardiovascular toxicity of allylamine. To test our hypothesis, we fed 150 mg kg allylamine to semicarbazide-pretreated (3 h; 98 mg kg) rats. Animals were sacrificed 1 h after allylamine treatment. Aorta, epicardium, and endocardium were assayed for SSAO, glutathione peroxidase, catalase, thiol status and lipid peroxidation. SSAO activity was decreased significantly in aorta, epicardium and endocardium. Activity was 30-times higher in aorta than in epicardium and endocardium. A striking decrease in malonalydehyde level (lipid peroxidation) was found in aorta of pretreated rats as compared to allylamine-only treated rats. The reduction of free-SH content in aortic mitochondria was also attenuated in pretreated rats. Changes were not so marked in epicardium and endocardium. These results suggest that in vivo pretreatment with semicarbazide at least partially protects aortic mitochondria from allylamine toxicity. The mechanism can be explained on the basis of the fact that semicarbazide inhibits acrolein formation in allylamine-treated rats.",
keywords = "Allylamine, Aorta, Cardiovascular toxicity, Lipid peroxidation, Semicarbazide, Semicarbazide-sensitive amine oxidase (SSAO)",
author = "S. Awasthi and Boor, {P. J.}",
year = "1993",
doi = "10.1016/0378-4274(93)90090-K",
language = "English (US)",
volume = "66",
pages = "157--163",
journal = "Toxicology Letters",
issn = "0378-4274",
publisher = "Elsevier BV",
number = "2",

}

TY - JOUR

T1 - Semicarbazide protection from in vivo oxidant injury of vascular tissue by allylamine

AU - Awasthi, S.

AU - Boor, P. J.

PY - 1993

Y1 - 1993

N2 - Allylamine is a specific cardiovascular toxin that causes vascular and myocardial lesions. Previous studies showed that allylamine-induced chronic lesions are markedly reduced by semicarbazide, an inhibitor of semicarbazide-sensitive amine oxidase (SSAO), and that allylamine is metabolized to the aldehyde, acrolein, by SSAO. We hypothesized that inhibitors of SSAO might reduce the acute cardiovascular toxicity of allylamine. To test our hypothesis, we fed 150 mg kg allylamine to semicarbazide-pretreated (3 h; 98 mg kg) rats. Animals were sacrificed 1 h after allylamine treatment. Aorta, epicardium, and endocardium were assayed for SSAO, glutathione peroxidase, catalase, thiol status and lipid peroxidation. SSAO activity was decreased significantly in aorta, epicardium and endocardium. Activity was 30-times higher in aorta than in epicardium and endocardium. A striking decrease in malonalydehyde level (lipid peroxidation) was found in aorta of pretreated rats as compared to allylamine-only treated rats. The reduction of free-SH content in aortic mitochondria was also attenuated in pretreated rats. Changes were not so marked in epicardium and endocardium. These results suggest that in vivo pretreatment with semicarbazide at least partially protects aortic mitochondria from allylamine toxicity. The mechanism can be explained on the basis of the fact that semicarbazide inhibits acrolein formation in allylamine-treated rats.

AB - Allylamine is a specific cardiovascular toxin that causes vascular and myocardial lesions. Previous studies showed that allylamine-induced chronic lesions are markedly reduced by semicarbazide, an inhibitor of semicarbazide-sensitive amine oxidase (SSAO), and that allylamine is metabolized to the aldehyde, acrolein, by SSAO. We hypothesized that inhibitors of SSAO might reduce the acute cardiovascular toxicity of allylamine. To test our hypothesis, we fed 150 mg kg allylamine to semicarbazide-pretreated (3 h; 98 mg kg) rats. Animals were sacrificed 1 h after allylamine treatment. Aorta, epicardium, and endocardium were assayed for SSAO, glutathione peroxidase, catalase, thiol status and lipid peroxidation. SSAO activity was decreased significantly in aorta, epicardium and endocardium. Activity was 30-times higher in aorta than in epicardium and endocardium. A striking decrease in malonalydehyde level (lipid peroxidation) was found in aorta of pretreated rats as compared to allylamine-only treated rats. The reduction of free-SH content in aortic mitochondria was also attenuated in pretreated rats. Changes were not so marked in epicardium and endocardium. These results suggest that in vivo pretreatment with semicarbazide at least partially protects aortic mitochondria from allylamine toxicity. The mechanism can be explained on the basis of the fact that semicarbazide inhibits acrolein formation in allylamine-treated rats.

KW - Allylamine

KW - Aorta

KW - Cardiovascular toxicity

KW - Lipid peroxidation

KW - Semicarbazide

KW - Semicarbazide-sensitive amine oxidase (SSAO)

UR - http://www.scopus.com/inward/record.url?scp=0027418850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027418850&partnerID=8YFLogxK

U2 - 10.1016/0378-4274(93)90090-K

DO - 10.1016/0378-4274(93)90090-K

M3 - Article

VL - 66

SP - 157

EP - 163

JO - Toxicology Letters

JF - Toxicology Letters

SN - 0378-4274

IS - 2

ER -